Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: A verification study

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 217-222

  Gately, K ^a   Al Alao, B ^a   Dhillon, T ^b   Mauri, F ^b   Cuffe, S ^a   Seckl, M ^b   O'Byrne, K ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b CR UK Laboratories   (United Kingdom)

Author keywords

Angioinvasion; Early stage NSCLC; Immunohistochemistry (IHC); Mammalian target of rapamycin (mTOR); MTOR inhibitors; Poor prognostic factor

Indexed keywords

BIOCHEMICAL MARKER; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RIDAFOROLIMUS; TEMSIROLIMUS;

ADULT; AGED; ANGIOINVASION; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSELS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TOR SERINE-THREONINE KINASES;

EID: 84855449478     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.06.012     Document Type: Article

References (46)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Pfannschmidt J., Muley T., Bülzebruck H., Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007, 55(March (3)):371-377.
3. Mok T.S., Zhou Q., Leung L., Loong H.H. Personalized medicine for non-small-cell lung cancer. Expert Rev Anticancer Ther 2010, 10(October (10)):1601-1611.
4. Roberts T.E., Hasleton P.S., Musgrove C., Swindell R., Lawson R.A. Vascular invasion in non-small cell lung carcinoma. J Clin Pathol 1992, 45:591-593.
5. Shields T.W. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 1983, 157:185-190.
6. Macchiarini P., Fontanini G., Hardin M.J., Chuanchieh H., Bigini D., Vignati S. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993, 106:80-89.
7. Pechet T.T.V., Carr S.R., Collins J.E., Cohn H.E., Farber J.L. Arterial invasion predicts early mortality in stage I non-small cell lung cancer. Ann Thorac Surg 2004, 78:1748-1754.
8. Tsuchiya T., Akamine S., Muraoka M., Kamohara R., Tsuji K., Urabe S., et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007, 56:341-348.
9. Ruffini E., Asioli S., Filosso P.L., Buffoni L., Bruna M.C., Mossetti C., et al. Significance of the presence of microscopic vascular invasion after complete resection of stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-size categories: did the 2009 7th edition of the TNM staging system miss something?. J Thorac Oncol 2011, 6(February (2)):319-326.
10. Chen J.S., Wang Q., Fu X.H., Huang X.H., Chen X.L., Cao L.Q., et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009, 39(February (2)):177-186.
11. Marinov M., Ziogas A., Pardo O.E., Tan L.T., Dhillon T., Mauri F.A., et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009, 15:1277-1287.
12. Dhillon T., Mauri F.A., Bellezza G., Cagini L., Barbareschi M., North B.V., et al. Overexpression of the mammalian target of rapamycin a novel marker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 2010, 5(3):314-319.
13. Sehgal S.N. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995, 17:660-665.
14. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
15. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
16. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
17. Shaw R.J., Cantley L.C. Ras PI(3)K, and mTOR signalling controls tumor cell growth. Nature 2006, 441:424-430.
18. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004, 25:2053-2059.
19. Wislez M., Spencer M.L., Izzo J.G., Juroske D.M., Balhara K., Cody D.D., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005, 65:3226-3235.
20. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13:4261-4270.
21. Cao C., Subhawong T., Albert J.M., Kim K.W., Geng L., Sekhar K.R., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006, 66:10040-10047.
22. Albert J.M., Kim K.W., Cao C., Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5:1183-1189.
23. Nagata Y., Takahashi A., Ohnishi K., Ota I., Ohnishi T., Tojo T., et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol 2010, 37(4):1001-1010.
24. Gomez-Martin C., Rubio-Viqueira B., Hidalgo M. Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer 2005, 7(Suppl. 1):S13-S18.
25. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111(6):1710-1717.
26. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40(April (2)):90-97.
27. Shi S.R., Key M.E., Kalra K.L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991, 39:741-748.
28. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
29. Therneau T., Grambsch P., Fleming T. Martingale-based residuals forsurvival models. Biometrika 1990, 77:147-160.
30. Anagnostou V.K., Bepler G., Syrigos G.N., Tanoue L., Gettinger S., Homer R.J., et al. High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 2009, 12:4157-4164.
31. Herberger B., Puhalla H., Lehnert M., Wrba F., Novak S., Brandstetter A., et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007, 13:4795-4799.
32. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
33. Oza A.M., Elit L., Biagi J., Chapman W., Tsao M., Hedley D. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. Proc Am Soc Clin Oncol 2006, 24(18S):3003.
34. Le Tourneau C., Faivre S., Serova M., Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?. Br J Cancer 2008, 99:1197-1203.
35. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo controlled phase III trial. Lancet 2008, 372:449-456.
36. O'Donnell A., Faivre S., Burris H.A., Rea D., Papadimitrakopoulou V., Shand N., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595.
37. Mita M.M., Mita A.C., Chu Q.S., Rowinsky E.K., Fetterly G.J., Goldston M., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008, 26:361-367.
38. Chang S.M., Wen P., Cloughesy T., Greenberg H., Schiff D., Conrad C., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23:357-361.
39. Margolin K., Longmate J., Baratta T., Synold T., Christensen S., Weber J., et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005, 104:1045-1048.
40. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
41. Milton D.T., Riely G.J., Azzoli C.G., Gomez J.E., Heelan R.T., Kris M.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced non small-cell lung cancer. Cancer 2007, 110(3):599-605.
42. Soria J.C., Shepherd F.A., Douillard J.Y., Wolf J., Giaccone G., Crino L., et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009, 20(10):1674-1681.
43. Edelman M.J., Watson D., Wang X., Morrison C., Kratzke R.A., Jewell S., et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+chemotherapy - cancer and leukemia group B trial 30203. J Clin Oncol 2008, 26(6):848-855.
44. Jassem J., Langer C.J., Karp D.D., Mok T., Benner R.J., Green S.J., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:7500.
45. Spigel D. Randomized multicenter double-blind placebo controlled phase II study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. ESMO 2010, [Abstract LBA15].
46. Campbell L., Jasani B., Edwards K., Gumbleton M., Griffiths D.F. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 2008, 98:931-940.